Skip to content

Precigen PGEN Proceeds From Sale And Maturity Of Available For Sale Securities

Proceeds From Sale And Maturity Of Available For Sale Securities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$359M+63.2%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's proceeds from sale and maturity of available for sale securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's proceeds from sale and maturity of available for sale securities?
Precigen (PGEN) reported proceeds from sale and maturity of available for sale securities of $55.1M in Q1 2026.
How has Precigen's proceeds from sale and maturity of available for sale securities changed year-over-year?
Precigen's proceeds from sale and maturity of available for sale securities increased by 1104.9% year-over-year, from $4.57M to $55.1M.
What is the long-term trend for Precigen's proceeds from sale and maturity of available for sale securities?
Over 4 years (2021 to 2025), Precigen's proceeds from sale and maturity of available for sale securities has grown at a 20.1% compound annual growth rate (CAGR), from $100.17M to $208.47M.